For weight management, NICE (TA875) recommends semaglutide 2.4 mg (Wegovy) only within specialist weight management services for adults with a BMI of at least 35 kg/m (or 30 kg/m with weight-related comorbidities) and as part of a supervised programme for a maximum of 2 years
Whether this risk applies to humans is not fully established, but the precaution is appropriate
"Many of my clients find that once they establish the routine of their weekly injection, it becomes a helpful reminder to check in with their nutrition goals for the week," notes Rita Faycurry, RD
Do they require prior authorization
For Wegovy, removing the pen before the yellow indicator stops moving can lead to underdosing
Decisions should be based on the patients metabolic health, cardiovascular risk, weight history, medications, family history, and overall clinical picture